Disease · MONDO_0005579

idiopathic generalized epilepsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. idiopathic generalized epilepsy. Diseases, record MONDO_0005579. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005579

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: idiopathic generalized epilepsy; Open Targets
Open Targets ID: MONDO_0005579; Open Targets
Other names: EIG, IGE, epilepsy, idiopathic generalized, generalised epilepsy, hereditary idiopathic generalized epilepsy, idiopathic generalised epilepsy; Open Targets
Disease Ontology: DOID:1827; Disease Ontology
MeSH: C562694; MeSH
Highest stage of its drugs: Phase 3, for 2 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
LACOSAMIDE	CHEMBL58323	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Unknown	https://conductscience.org/library/genes/7915	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6332	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01228747	A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)	Phase 3	361	2015-05-13	Epilepsy, Generalized Tonic-Clonic Seizures	LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov
NCT02408523	A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications	Phase 3	242	2020-04-16	Epilepsy	LACOSAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02408549	Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures	Phase 3	239	2023-12-14	Epilepsy	LACOSAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01118962	Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy	Phase 2	39	2013-12-04	Epilepsy	LACOSAMIDE	Its record names the disease	ClinicalTrials.gov
NCT06393309	Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy		169		Treatment of Idiopathic Generalized Epilepsy	LEVETIRACETAM, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00160550	Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures	Phase 3	154		Generalized Convulsive Epilepsy	LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov
NCT00150774	Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults	Phase 3	116		Generalized Convulsive Epilepsy	LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Levetiracetam vs Placebo: serious adverse events	1 of 126	4 of 125	251	NCT01228747	Trial comparisons
Levetiracetam vs Placebo: Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period	91 of 117	31 of 109	226	NCT01228747	Trial comparisons
Levetiracetam vs Placebo: Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Evaluation Period	82 of 108	33 of 97	205	NCT01228747	Trial comparisons
Levetiracetam vs Placebo: Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period	32 of 108	3 of 97	205	NCT01228747	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30525116	RESULT	1	PubMed
28086164	RESULT	1	PubMed
19327967	RESULT	2	PubMed
18285535	RESULT	1	PubMed
17625106	RESULT	1	PubMed
39460685	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005579

GET https://conductscience.org/api/diseases/v1/MONDO_0005579/drugs

API reference For AI assistants